‘Our favourite drug’: prevalence of use and preference for mephedrone in the London night-time economy 1 year after control

References

• Dargan, P. I., Albert, S., & Wood, D. M. (2010). Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. Quarterly Journal of Medicine, 103(11), 875–879.
   Google Scholar
• Dargan, P. I., Hudson, S., Ramsey, J., & Wood, D. M. (2011a). The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in ‘Spice’. International Journal of Drug Policy, 22(4), 274–277.
   PubMed Web of Science ®Google Scholar
• Dargan, P. I., Sedefov, R., Gallegos, A., & Wood, D. M. (2011b). The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Testing and Analysis, 3(7–8), 454–463.
   PubMed Web of Science ®Google Scholar
• European Union Council Decision. (2010). COUNCIL DECISION of 2 December 2010 on submitting 4-methylmethcathinone (mephedrone) to control measures (2010/759/EU)2. Retrieved from http://eur-lex.europa.eu/LmexUriServ/LexUriServ.do?uri==OJ:L:2010:322:0044:0045:en:PDF
   Google Scholar
• Hoare, J., & Moon, D. (2010). Drug misuse declared: Findings from the 2009/10 British Crime Survey, England and Wales. Home Office Statistical Bulletin 13/10. London: Home Office. Retrieved from http://www.homeoffice.gov.uk/rds/pdfs10/hosb1310.pdf
   Google Scholar
• Hughes, C., & Stevens, A. (2010). What can we learn from the Portuguese decriminalization of illicit drugs? British Journal of Criminology, 50(6), 999–1022.
   Web of Science ®Google Scholar
• James, D., Adams, R. D., Spears, R., Cooper, G., Lupton, D. J., Thompson, J. P., & Thomas, S. H.; on behalf of the National Poisons Information Service. (2011). Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emergency Medicine Journal, 28(8), 686–689.
   PubMed Web of Science ®Google Scholar
• Liechti, M. E., Kunz, I., Greminger, P., Speich, R., & Kupferschmidt, H. (2006). Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use. Drug and Alcohol Dependence, 81(3), 323–326.
   PubMed Web of Science ®Google Scholar
• Measham, F., Aldridge, J., & Parker, H. (2001). Dancing on drugs: Risk, health and hedonism in the British Club Scene. London: Free Association Books.
   Google Scholar
• Measham, F., & Brain, K. (2005). ‘Binge’ drinking, British alcohol policy and the new culture of intoxication. Crime, Media, Culture: An International Journal, 1(3), 263–284.
   Google Scholar
• Measham, F., & Moore, K. (2009). Repertoires of distinction: Exploring patterns of weekend polydrug use within local leisure scenes across the English night time economy. Criminology & Criminal Justice, 9(4), 437–464.
   Web of Science ®Google Scholar
• Measham, F., Moore, K., Newcombe, R., & Welch, Z. (2010). Tweaking, bombing, dabbing and stockpiling: The emergence of mephedrone and the perversity of prohibition. Drugs and Alcohol Today, 10(1), 14–21.
   Google Scholar
• Measham, F., Moore, K., & Østergaard, J. (2011a). Mephedrone, ‘Bubble’ and unidentified white powders: The contested identities of synthetic ‘legal highs’. Drugs and Alcohol Today, 11(3), 137–147.
   Google Scholar
• Measham, F., Wood, D., Dargan, P., & Moore, K. (2011b). The rise in legal highs: Prevalence and patterns in the use of illegal drugs and first and second generation ‘legal highs’ in south London gay dance clubs. Journal of Substance Use, 16(4), 263–272.
   Web of Science ®Google Scholar
• Morin, S., & Collins, C. (2000). Substance abuse prevention: Moving from science to policy. Addictive Behaviors, 25, 975–983.
   PubMed Web of Science ®Google Scholar
• Reinarman, C., Cohen, P., & Kaal, H. (2004). The limited relevance of drug policy: Cannabis in Amsterdam and in San Francisco. American Journal of Public Health, 94(5), 836–842.
   PubMed Web of Science ®Google Scholar
• Smith, K., & Flatley, J. (Eds.) (2011). Drug misuse declared: Findings from the 2010/11 British Crime Survey, England and Wales. Home Office Statistical Bulletin 12/11. London: Home Office. Retrieved from http://www.statistics.gov.uk
   Google Scholar
• Winstock, A., Mitcheson, L., & Marsden, J. (2010). Mephedrone: Still available and twice the price. Lancet, 376(9752), 1537.
   PubMed Web of Science ®Google Scholar
• Wodak, A., Reinarman, C., & Cohen, P. (2002). Cannabis control: Costs outweigh the benefits. British Medical Journal, 324, 105–108.
   PubMed Web of Science ®Google Scholar
• Wood, D. M., Davies, S., Greene, S. L., Button, J., Holt, D. W., Ramsey, J., & Dargan, P. I. (2010a). Case series of individuals with analytically confirmed acute mephedrone toxicity. Clinical Toxicology (Philadelphia, PA), 48(9), 924–927.
   PubMed Web of Science ®Google Scholar
• Wood, D. M., Davies, S., Puchnaewicz, M., Button, J., Archer, R., Ovaska, H., Ramsey, J., Lee, T., Holt, D. W., & Dargan, P. I. (2010b). Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. Journal of Medical Toxicology, 6(3), 327–330.
   PubMedGoogle Scholar
• Wood, D. M., Greene, S. L., & Dargan, P. I. (2011a). Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emergency Medicine Journal, 28(4), 280–282.
   PubMed Web of Science ®Google Scholar
• Wood, D. M., Greene, S. L., & Dargan, P. I. (2011b). Emergency department presentations in determining the effectiveness of drug control in the United Kingdom: Mephedrone (4-methylmethcathinone) control appears to be effective using this model. Emergency Medicine Journal, In press.
   Google Scholar
• Wood, D. M., Warren-Gash, C., Ashraf, T., Greene, S. L., Shather, Z., Trivedy, C., Clarke, S., Ramsey, J., Holt, D. W., & Dargan, P. I. (2008). Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD). Quarterly Journal of Medicine, 101(1), 23–29.
   Google Scholar